Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vifor Pharma Group

www.viforpharma.com

Latest From Vifor Pharma Group

AstraZeneca's Dobber On Ramping In Renal, Expanding In CV And Business Development

Biopharmaceuticals President Ruud Dobber talked to Scrip about the launches of Lokelma and roxadustat in kidney disease, building with a high bar in cardiovascular disease and expanding in cell and gene therapy.

Business Strategies Leadership

NICE Increases Options For Hyperkalemia Patients In England

Patients with high levels of blood potassium in England have two more options for treating their condition after NICE reversed its earlier negative recommendations. 

United Kingdom Europe

Deal Watch: Allergan Keeps After Hair Loss With Exicure Deal

Allergan has tried to go after alopecia in the past; Exicure brings a new spherical nucleic acid (SNA) technology. In other recent deals, AstraZeneca sells Seroquel, Losec rights to Germany’s Cheplapharm.

Deals Business Strategies

Evotec, Vifor JV To Fight Kidney Disease

Evotec’s CSO says its new joint venture with Vifor will use patient-driven data to identify and develop targeted therapies to treat kidney disease with.

Commercial Companies
See All

Company Information

UsernamePublicRestriction

Register